Onkologie. 2022:16(5):254-257 | DOI: 10.36290/xon.2022.048

Proton therapy in the treatment of meningiomas

Stěpan Vinakurau1, Renata Emmerová2
1 Proton Therapy Center Czech s. r. o., Praha
2 Odděleni klinické a radiační onkologie, Krajská nemocnice Liberec, a. s.

Meningiomas are among the most common tumors of the brain and spinal cord. Invasive (neurosurgical) and non-invasive (radiothera­py) methods are used in the treatment. Radiotherapy can be delivered by stereotactic or non-stereotactic methods, with photons or particles (protons or carbon ions). Proton therapy uses the physical properties of protons to spare non-target brain tissues.

Keywords: meningiomas, benign meningiomas, atypical meningeomas, anaplastic meningiomas, radiotherapy, proton beam therapy, frakcionated radiotherapy.

Accepted: September 29, 2022; Published: September 29, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vinakurau S, Emmerová R. Proton therapy in the treatment of meningiomas. Onkologie. 2022;16(5):254-257. doi: 10.36290/xon.2022.048.
Download citation

References

  1. Buerki RA, Horbinski CM, Kruser T, et al. An overview of meningiomas. Future Oncol. 2018;14(21):2161-2177. doi: 10.2217/fon-2018-0006. Epub 2018 Aug 7. PMID: 30084265; PMCID: PMC6123887. Go to original source... Go to PubMed...
  2. Aizer AA, Abedalthagafi M, Bi WL, et al. A prognostic cytogenetic scoring system to guide the adjuvant management of patients with atypical meningioma. Neuro Oncol. 2016;18(2):269-274. Go to original source... Go to PubMed...
  3. Nassiri F, Mamatjan Y, Suppiah S, et al. DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management. Neuro Oncol. 2019;21(7):901-910. Go to original source... Go to PubMed...
  4. Spiegl-Kreinecker S, Lötsch D, Neumayer K, et al. TERT promoter mutations are associated with poor prognosis and cell immortalization in meningioma. 2018;20(12):1584-1593.
  5. Rachinger W, Stoecklein VM, Terpolilli NA, et al. Increased 68Ga-DOTATATE uptake in PET imaging discriminates meningioma and tumor-free tissue. J Nucl Med. 2015;56(3):347-353. doi: 10.2967/jnumed.114.149120. Epub 2015 Jan 29. PMID: 25635133. Go to original source... Go to PubMed...
  6. Milker-Zabel S, Zabel-du Bois A, Henze M, et al. Improved target volume definition for fractionated stereotactic radiotherapy in patients with intracranial meningiomas by correlation of CT, MRI, and [68Ga]-DOTATOC-PET. Int J Radiat Oncol Biol Phys. 2006;65(1):222-227. Go to original source... Go to PubMed...
  7. Stade F, Dittmar JO, Jakel O, et al. Influence of (68)Ga-DOTATOC on sparing of normal tissue for radiation therapy of skull base meningioma: differential impact of photon and proton radiotherapy. Radiat Oncol [Internet]. 2018;13(1):58 [cited 1.1.2021]. doi: 10.1186/s13014-018-1008-z. Go to original source... Go to PubMed...
  8. Bosnyák E, Kamson DO, Guastella AR, Varadarajan K, Robinette NL, Kupsky WJ, Muzik O, Michelhaugh SK, Mittal S, Juhász C. Molecular imaging correlates of tryptophan metabolism via the kynurenine pathway in human meningiomas. Neuro Oncol. 2015;17(9):1284-1292. doi: 10.1093/neuonc/nov098. Epub 2015 Jun 18. PMID: 26092774; PMCID: PMC4588760. Go to original source... Go to PubMed...
  9. Galldiks N, Angenstein F, Werner JM, et al. Use of advanced neuroimaging and artificial intelligence in meningiomas. Brain Pathol. 2022;32(2):e13015. doi: 10.1111/bpa.13015. PMID: 35213083; PMCID: PMC8877736. Go to original source... Go to PubMed...
  10. Weber DC, Bizzocchi N, Bolsi A, Jenkinson MD. Proton Therapy for Intracranial Meningioma for the Treatment of Primary/Recurrent Disease Including Re-Irradiation. Front Oncol. 2020;10:558845. Go to original source... Go to PubMed...
  11. Arvold ND, Niemierko A, Broussard GP, Adams J, Fullerton B, Loeffler JS, Shih HA. Projected second tumor risk and dose to neurocognitive structures after proton versus photon radiotherapy for benign meningioma. Int J Radiat Oncol Biol Phys. 2012;83(4):e495-500. Go to original source... Go to PubMed...
  12. Chung CS, Yock TI, Nelson K, Xu Y, Keating NL, Tarbell NJ. Incidence of second malignancies among patients treated with proton versus photon radiation. Int J Radiat Oncol Biol Phys. 2013;87(1):46-52. Go to original source... Go to PubMed...
  13. Monje ML, Mizumatsu S, Fike JR, et al. Irradiation induces neural precursor-cell dysfunction. Nat Med. 2002;8: 955-962. Go to original source... Go to PubMed...
  14. Petersson K, Gebre-Medhin M, Ceberg C, et al. Haematological toxicity in adult patients receiving craniospinal irradiation--indication of a dose-bath effect. Radiother Oncol. 2014;111(1):47-51. Go to original source... Go to PubMed...
  15. Murray FR, Snider JW, Bolsi A, et al. LongTerm Clinical Outcomes of Pencil Beam Scanning Proton Therapy for Benign and Non-benign Intracranial Meningiomas. Int J Radiat Oncol Biol Phys. 2017;99(5):1190-1198. Go to original source... Go to PubMed...
  16. Wenkel E, Thornton AF, Finkelstein D, et al. Benign meningioma: partially resected, biopsied, and recurrent intracranial tumors treated with combined proton and photon radiotherapy. Int J Radiat Oncol Biol Phys. 2000;48(5):1363-1370. Go to original source... Go to PubMed...
  17. McDonald MW, Plankenhorn DA, McMullen KP, et al. Proton therapy for atypical meningiomas. J Neurooncol. 2015;123(1):123-128. Go to original source... Go to PubMed...
  18. Chan AW, Bernstein KD, Adams JA, Parambi RJ, Loeffler JS. Dose escalation with proton radiation therapy for high-grade meningiomas. Technol Cancer Res Treat. 2012;11(6):607-614. Go to original source... Go to PubMed...
  19. Verma V, Simone CB, Mishra MV. Quality of life and patient-reported outcomes following proton radiation therapy: a systematic review. J Natl Cancer Inst. 2018;110:341-353. Go to original source... Go to PubMed...
  20. de Kruijff RM. FLASH radiotherapy: ultra-high dose rates to spare healthy tissue. Int J Radiat Biol. 2020;96(4):419-423. Go to original source... Go to PubMed...




Oncology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.